BR112016017764A2 - anticorpo antidengue de amplo espectro - Google Patents

anticorpo antidengue de amplo espectro

Info

Publication number
BR112016017764A2
BR112016017764A2 BR112016017764A BR112016017764A BR112016017764A2 BR 112016017764 A2 BR112016017764 A2 BR 112016017764A2 BR 112016017764 A BR112016017764 A BR 112016017764A BR 112016017764 A BR112016017764 A BR 112016017764A BR 112016017764 A2 BR112016017764 A2 BR 112016017764A2
Authority
BR
Brazil
Prior art keywords
antibody
antibody agents
antidengue
broad spectrum
serotypes
Prior art date
Application number
BR112016017764A
Other languages
English (en)
Portuguese (pt)
Inventor
Tharakaraman Kannan
Sasisekharan Ram
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of BR112016017764A2 publication Critical patent/BR112016017764A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112016017764A 2014-02-11 2015-02-11 anticorpo antidengue de amplo espectro BR112016017764A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461938605P 2014-02-11 2014-02-11
PCT/US2015/015510 WO2015123362A1 (en) 2014-02-11 2015-02-11 Novel full spectrum anti-dengue antibody

Publications (1)

Publication Number Publication Date
BR112016017764A2 true BR112016017764A2 (pt) 2017-10-10

Family

ID=53800606

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016017764A BR112016017764A2 (pt) 2014-02-11 2015-02-11 anticorpo antidengue de amplo espectro

Country Status (12)

Country Link
US (3) US9902764B2 (enExample)
EP (1) EP3104888A4 (enExample)
JP (1) JP6707455B2 (enExample)
KR (1) KR20160119806A (enExample)
CN (1) CN106413749B (enExample)
AU (1) AU2015217149B2 (enExample)
BR (1) BR112016017764A2 (enExample)
CA (1) CA2938495A1 (enExample)
IL (1) IL246788A0 (enExample)
MX (1) MX375402B (enExample)
SG (2) SG10201807826XA (enExample)
WO (1) WO2015123362A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
KR102165384B1 (ko) 2012-08-07 2020-10-16 메사추세츠 인스티튜트 오브 테크놀로지 항-뎅기 바이러스 항체 및 이들의 용도
CA3212977A1 (en) 2014-02-11 2015-08-20 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
CA2938495A1 (en) * 2014-02-11 2015-08-20 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
CN109311986A (zh) 2016-03-25 2019-02-05 威特拉公司 登革热病毒抗体分子的制剂
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP2022008719A (ja) * 2016-11-23 2022-01-14 セルヴァス エーアイ インコーポレイテッド 疾患発症予測方法及び装置
US20200131251A1 (en) 2016-12-23 2020-04-30 Serum Institute Of India Private Limited Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
IL277375B2 (en) 2018-03-15 2025-08-01 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
DK0804070T3 (da) 1993-03-09 2000-08-07 Genzyme Corp Fremgangsmåde til isolering af proteiner fra mælk
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JPH07299655A (ja) 1994-04-30 1995-11-14 Aisin Seiki Co Ltd 内スプライン歯面仕上機
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
CN1305905C (zh) 2002-03-22 2007-03-21 Aprogen株式会社 人源化抗体及其制备方法
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
DK1556477T3 (en) 2002-11-01 2017-10-23 Glaxosmithkline Biologicals Sa Process for drying
CA2894300A1 (en) 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secreatary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2007021672A2 (en) 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
DK2257624T5 (da) 2008-02-05 2012-09-10 Medical Res Council Fremgangsmåder og sammensætninger
KR20110061624A (ko) * 2008-10-05 2011-06-09 더 보드 오브 트러스티즈 오프 더 리랜드 스탠포드 쥬니어 유니버시티 Ｃ형 간염 항체 및 이의 용도
NZ592054A (en) 2008-10-13 2013-06-28 Inst Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
JP2012511026A (ja) 2008-12-05 2012-05-17 エルパス・インコーポレイテッド 抗脂抗体結晶構造を用いた抗体設計
WO2010093335A1 (en) 2009-02-10 2010-08-19 Nanyang Technological University Antibodies for diagnosis and treatment of flaviviral infections
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US8637035B2 (en) 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
US20140349321A1 (en) 2011-12-16 2014-11-27 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
US9556254B2 (en) * 2012-05-14 2017-01-31 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cross-reactive antibodies against dengue virus and uses thereof
KR102165384B1 (ko) * 2012-08-07 2020-10-16 메사추세츠 인스티튜트 오브 테크놀로지 항-뎅기 바이러스 항체 및 이들의 용도
CA3212977A1 (en) 2014-02-11 2015-08-20 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
CA2938495A1 (en) * 2014-02-11 2015-08-20 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody

Also Published As

Publication number Publication date
CN106413749B (zh) 2022-04-05
SG10201807826XA (en) 2018-10-30
SG11201606163QA (en) 2016-08-30
CN106413749A (zh) 2017-02-15
US9902764B2 (en) 2018-02-27
EP3104888A4 (en) 2017-08-09
KR20160119806A (ko) 2016-10-14
US20180237504A1 (en) 2018-08-23
CA2938495A1 (en) 2015-08-20
IL246788A0 (en) 2016-08-31
US11421018B2 (en) 2022-08-23
US20200207841A1 (en) 2020-07-02
EP3104888A1 (en) 2016-12-21
WO2015123362A1 (en) 2015-08-20
AU2015217149A1 (en) 2016-09-08
JP6707455B2 (ja) 2020-06-10
JP2017507131A (ja) 2017-03-16
MX375402B (es) 2025-03-06
MX2016009991A (es) 2016-10-07
US20150368321A1 (en) 2015-12-24
US10519220B2 (en) 2019-12-31
AU2015217149B2 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
BR112016017764A2 (pt) anticorpo antidengue de amplo espectro
MX2019008736A (es) Anticuerpos anti-virus del dengue y usos de los mismos.
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
AR134186A2 (es) Un anticuerpo anti-csf-1r, un proceso para producirlo, una composición farmacéutica que lo comprende, una secuencia de adn aislado, un vector de expresión o clonación y una célula hospedadora
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201891344A1 (ru) Новые агонисты рецептора апелина и способы применения
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
BR112018002844A2 (pt) receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos
CU20180024A7 (es) Moléculas de unión a linfopoyetina estromal tímica (tslp), composiciones farmacéuticas que las contienen y método de producción de las mismas
BR112018067696A2 (pt) membros de ligação à pd-l1
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
EA201791270A1 (ru) Модифицированные april-связывающие антитела
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
PL422231A1 (pl) Komórki immunologiczne CAR do leczenia nowotworów
EA201892123A1 (ru) 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj
EA201891336A1 (ru) Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj
EA201592203A1 (ru) Способы лечения таупатии
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.